Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02743819 |
| Title | Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | University of Chicago |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |